---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-053987"
form_type: "8-K"
ticker: "ORKA"
cik: "0000907654"
company_name: "Oruka Therapeutics, Inc."
filed_at: "2023-10-18T23:59:59+00:00"
generated_at: "2026-06-09T22:17:30.331850+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# ARCA biopharma reports Q3 2023 net loss of $1.4M; cash $38.5M sufficient through end of 2024

## Summary
- Net loss of $1.4M ($0.10/share) vs $2.3M ($0.16/share) in Q3 2022; operating expenses down to $2.0M from $2.6M.
- Cash and equivalents $38.5M at Sep 30, 2023 (down from $42.4M at Dec 31, 2022); funding runway through end of 2024.
- R&D expenses fell to $0.3M from $1.0M YoY due to prior 67% workforce reduction (12 employees) in July 2022.
- Strategic review process with Ladenburg Thalmann continues; no defined timeline and may not result in a transaction.

## SEC filing metadata
- accession: 0000950170-23-053987
- form_type: 8-K
- ticker: ORKA
- cik: 0000907654
- company_name: Oruka Therapeutics, Inc.
- filed_at: 2023-10-18T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/907654/000095017023053987/0000950170-23-053987-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/907654/000095017023053987/abio-20231018.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-053987
- JSON: https://secwatch.observer/filing/0000950170-23-053987.json
- Plain text: https://secwatch.observer/filing/0000950170-23-053987.txt

## Key facts
- Earnings Releases
  Oruka Therapeutics, Inc. reported quarter ended September 30, 2023 results: net income $1.4 million, EPS $0.10 per basic and diluted share.
  - Period: quarter ended September 30, 2023
  - Net income: $1.4 million
  - EPS: $0.10 per basic and diluted share
  - Result: reported results
  source text: Net loss for the quarter ended September 30, 2023 was $1.4 million, or $0.10 per basic and diluted share, compared to $2.3 million, or $0.16 per basic and diluted share in the third quarter of 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/907654/000095017023053987/0000950170-23-053987-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.